Roivant SciencesROIVW -3.85%55 Days Payable is 4,462.13 as of Mar. 2026, which is 13% below its 10-year median of 5,137.32. GuruFocus rates ROIVW with a GF Score™ of 55/100. The stock has 7 warning signs investors should review. Among 707 Biotechnology companies, Roivant Sciences ranks better than 93.64% on this metric.
The historical rank and industry rank for Roivant Sciences's Days Payable or its related term are showing as below:
ROIVW'
s Days Payable Range Over the Past 10 Years
Min: 1122.21 Med: 5137.32 Max: 7556.42
Current: 4635.7
During the past 6 years, Roivant Sciences's highest Days Payable was 7556.42. The lowest was 1122.21. And the median was 5137.32.
ROIVW's Days Payable is ranked better than 93.64% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs ROIVW: 4635.70
Roivant Sciences's Days Payable
declined
from Mar. 2025 (10,550.06) to Mar. 2026 (4,462.13).
It may suggest that Roivant Sciencesaccelerated paying its suppliers.
Roivant Sciences Days Payable Related Terms
Roivant Sciences Days Payable Historical Data
* Premium members only.
The historical data trend for Roivant Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROIVW vs INSM, INCY, BNTX: Days Payable Comparison
For the Biotechnology subindustry, Roivant Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roivant Sciences Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Roivant Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Roivant Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Roivant Sciences's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roivant Sciences (ROIVW) has a Days Payable of 4,462.13 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Roivant Sciences and its competitors. This is 13% below median its historical median of 5,137.32. Over the past decade, Roivant Sciences' Days Payable has ranged from 1,122.21 to 7,556.42. According to the industry distribution chart, Roivant Sciences ranks #45 out of 707 companies in the Biotechnology industry, placing it in the top 6.4%.
Is Roivant Sciences' Days Payable too high?
Roivant Sciences' current Days Payable of 4,462.13 is 13% below median its 10-year median of 5,137.32. Over the past 10 years, this metric has ranged from a low of 1,122.21 to a high of 7,556.42. The Biotechnology industry median Days Payable is 113.76. Roivant Sciences' value of 4,462.13 is 3822.4% above this industry median. Based on the distribution chart, Roivant Sciences ranks #45 out of 707 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Roivant Sciences has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Days Payable compare to INSM and INCY?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #45 out of 707 companies for Days Payable. This places Roivant Sciences in the top 6% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.76. Roivant Sciences' value of 4,462.13 is 3822.4% above this benchmark. Historically, Roivant Sciences' own Days Payable has ranged from 1,122.21 to 7,556.42 over the past decade. While the company's 10-year median is 5,137.32 vs. the industry median of 113.76, Roivant Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roivant Sciences's current Days Payable of 4,462.13 is 3822.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Roivant Sciences and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roivant Sciences's current Days Payable is 4,462.13, which is 13% below median its own 10-year median of 5,137.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Roivant Sciences (ROIVW) has a current Days Payable of 4,462.13. The current Days Payable is 4,462.13, which is 13% below median its 10-year median of 5,137.32 and 3822.4% above the Biotechnology industry median of 113.76. Roivant Sciences' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Roivant Sciences (ROIVW), the current Days Payable is 4,462.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score
Get the complete analysis for ROIVW
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROIVW has been successfully added to your 
